TY - JOUR AU - Siegel, R. PY - 2014 DA - 2014// TI - Cancer statistics, 2014 JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21208 DO - 10.3322/caac.21208 ID - Siegel2014 ER - TY - JOUR AU - Boeger, H. PY - 2005 DA - 2005// TI - Structural basis of eukaryotic gene transcription JO - FEBS Lett VL - 579 UR - https://doi.org/10.1016/j.febslet.2004.11.027 DO - 10.1016/j.febslet.2004.11.027 ID - Boeger2005 ER - TY - JOUR AU - Gilks, C. B. AU - Prat, J. PY - 2009 DA - 2009// TI - Ovarian carcinoma pathology and genetics: recent advances JO - Hum Pathol VL - 40 UR - https://doi.org/10.1016/j.humpath.2009.04.017 DO - 10.1016/j.humpath.2009.04.017 ID - Gilks2009 ER - TY - JOUR AU - Venkitaraman, A. R. PY - 2001 DA - 2001// TI - Functions of BRCA1 and BRCA2 in the biological response to DNA damage JO - J Cell Sci VL - 114 ID - Venkitaraman2001 ER - TY - JOUR AU - Wooster, R. PY - 1995 DA - 1995// TI - Identification of the breast-cancer susceptibility gene Brca2 JO - Nature VL - 378 UR - https://doi.org/10.1038/378789a0 DO - 10.1038/378789a0 ID - Wooster1995 ER - TY - JOUR AU - Miki, Y. PY - 1994 DA - 1994// TI - A strong candidate for the breast and ovarian-cancer susceptibility gene Brca1 JO - Science VL - 266 UR - https://doi.org/10.1126/science.7545954 DO - 10.1126/science.7545954 ID - Miki1994 ER - TY - JOUR AU - Mersch, J. PY - 2015 DA - 2015// TI - Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29041 DO - 10.1002/cncr.29041 ID - Mersch2015 ER - TY - JOUR AU - Chambon, P. AU - Weill, J. D. AU - Mandel, P. PY - 1963 DA - 1963// TI - Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme JO - Biochem Biophys Res Commun VL - 11 UR - https://doi.org/10.1016/0006-291X(63)90024-X DO - 10.1016/0006-291X(63)90024-X ID - Chambon1963 ER - TY - JOUR AU - D'Amours, D. PY - 1999 DA - 1999// TI - Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions JO - Biochem J VL - 342 UR - https://doi.org/10.1042/bj3420249 DO - 10.1042/bj3420249 ID - D'Amours1999 ER - TY - JOUR AU - Rouleau, M. PY - 2010 DA - 2010// TI - PARP inhibition: PARP1 and beyond JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2812 DO - 10.1038/nrc2812 ID - Rouleau2010 ER - TY - JOUR AU - Kim, M. Y. AU - Zhang, T. AU - Kraus, W. L. PY - 2005 DA - 2005// TI - Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD(+) into a nuclear signal JO - Genes Dev VL - 19 UR - https://doi.org/10.1101/gad.1331805 DO - 10.1101/gad.1331805 ID - Kim2005 ER - TY - JOUR AU - Schreiber, V. PY - 1992 DA - 1992// TI - The human poly(ADP-ribose) polymerase nuclear localization signal is a bipartite element functionally separate from DNA binding and catalytic activity JO - EMBO J VL - 11 ID - Schreiber1992 ER - TY - JOUR AU - Valerie, K. AU - Povirk, L. F. PY - 2003 DA - 2003// TI - Regulation and mechanisms of mammalian double-strand break repair JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1206679 DO - 10.1038/sj.onc.1206679 ID - Valerie2003 ER - TY - JOUR AU - Stecklein, S. R. PY - 2012 DA - 2012// TI - BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1203326109 DO - 10.1073/pnas.1203326109 ID - Stecklein2012 ER - TY - JOUR AU - Ghosal, G. AU - Chen, J. PY - 2013 DA - 2013// TI - DNA damage tolerance: a double-edged sword guarding the genome JO - Transl Cancer Res VL - 2 ID - Ghosal2013 ER - TY - JOUR AU - Zaremba, T. AU - Curtin, N. J. PY - 2007 DA - 2007// TI - PARP inhibitor development for systemic cancer targeting JO - Anticancer Agents Med Chem VL - 7 UR - https://doi.org/10.2174/187152007781668715 DO - 10.2174/187152007781668715 ID - Zaremba2007 ER - TY - STD TI - Diavova II, DIanov GL Poly(ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim Pol, 2003. 50 (1): p. 169–79. ID - ref17 ER - TY - JOUR AU - Pommier, Y. PY - 2013 DA - 2013// TI - Drugging topoisomerases: lessons and challenges JO - ACS Chem Biol VL - 8 UR - https://doi.org/10.1021/cb300648v DO - 10.1021/cb300648v ID - Pommier2013 ER - TY - JOUR AU - Murai, J. PY - 2012 DA - 2012// TI - Trapping of PARP1 and PARP2 by clinical PARP inhibitors JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-2753 DO - 10.1158/0008-5472.CAN-12-2753 ID - Murai2012 ER - TY - STD TI - Hopkins TA, et al. Mechanistic dissection of PARP1 trapping and the impact onin vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015;13:1465–77. ID - ref20 ER - TY - JOUR AU - Kim, G. PY - 2015 DA - 2015// TI - FDA approval summary: olaparib Monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0887 DO - 10.1158/1078-0432.CCR-15-0887 ID - Kim2015 ER - TY - JOUR AU - Fong, P. C. PY - 2010 DA - 2010// TI - Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.9589 DO - 10.1200/JCO.2009.26.9589 ID - Fong2010 ER - TY - JOUR AU - Kaufman, B. PY - 2015 DA - 2015// TI - Olaparib Monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2728 DO - 10.1200/JCO.2014.56.2728 ID - Kaufman2015 ER - TY - JOUR AU - Lee, J. M. PY - 2014 DA - 2014// TI - Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses JO - J Natl Cancer Inst VL - 106 UR - https://doi.org/10.1093/jnci/dju089 DO - 10.1093/jnci/dju089 ID - Lee2014 ER - TY - STD TI - Oza AM, et al. laparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. Journal of Clinical Oncology. 2012;30(15):Suppl 5001. ID - ref25 ER - TY - JOUR AU - Oza, A. M. PY - 2015 DA - 2015// TI - Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71135-0 DO - 10.1016/S1470-2045(14)71135-0 ID - Oza2015 ER - TY - JOUR AU - Rajan, A. PY - 2012 DA - 2012// TI - A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2425 DO - 10.1158/1078-0432.CCR-11-2425 ID - Rajan2012 ER - TY - JOUR AU - Ledermann, J. PY - 2012 DA - 2012// TI - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1105535 DO - 10.1056/NEJMoa1105535 ID - Ledermann2012 ER - TY - JOUR AU - Ledermann, J. PY - 2014 DA - 2014// TI - Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70228-1 DO - 10.1016/S1470-2045(14)70228-1 ID - Ledermann2014 ER - TY - JOUR AU - Burger, R. A. PY - 2007 DA - 2007// TI - Phase II trial of Bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.5345 DO - 10.1200/JCO.2007.11.5345 ID - Burger2007 ER - TY - JOUR AU - Tentori, L. PY - 2007 DA - 2007// TI - Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2007.07.010 DO - 10.1016/j.ejca.2007.07.010 ID - Tentori2007 ER - TY - JOUR AU - Liu, J. F. PY - 2014 DA - 2014// TI - Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70391-2 DO - 10.1016/S1470-2045(14)70391-2 ID - Liu2014 ER - TY - JOUR AU - Sui, H. PY - 2015 DA - 2015// TI - Combination of Erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy JO - Drug Des Devel Ther VL - 9 UR - https://doi.org/10.2147/DDDT.S82035 DO - 10.2147/DDDT.S82035 ID - Sui2015 ER - TY - JOUR AU - Donawho, C. K. PY - 2007 DA - 2007// TI - ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-3039 DO - 10.1158/1078-0432.CCR-06-3039 ID - Donawho2007 ER - TY - JOUR AU - Kummar, S. PY - 2015 DA - 2015// TI - Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2565 DO - 10.1158/1078-0432.CCR-14-2565 ID - Kummar2015 ER - TY - JOUR AU - Coleman, R. L. PY - 2015 DA - 2015// TI - A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study JO - Gynecol Oncol VL - 137 UR - https://doi.org/10.1016/j.ygyno.2015.03.042 DO - 10.1016/j.ygyno.2015.03.042 ID - Coleman2015 ER - TY - JOUR AU - Mehta, M. P. PY - 2015 DA - 2015// TI - Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study JO - J Neurooncol VL - 122 UR - https://doi.org/10.1007/s11060-015-1733-1 DO - 10.1007/s11060-015-1733-1 ID - Mehta2015 ER - TY - STD TI - Middleton MR, et al. Randomized Phase 2 Study Evaluating Veliparib (ABT-888) With Temozolomide in Patients With Metastatic Melanoma. Ann Oncol, 2015. 26 (10). DOI: 10.1093/annonc/mdv308. ID - ref38 ER - TY - JOUR AU - Owonikoko, T. K. PY - 2015 DA - 2015// TI - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: a trial of the ECOG-ACRIN cancer research group (E2511) JO - Lung Cancer VL - 89 UR - https://doi.org/10.1016/j.lungcan.2015.04.015 DO - 10.1016/j.lungcan.2015.04.015 ID - Owonikoko2015 ER - TY - JOUR AU - Reiss, K. A. PY - 2015 DA - 2015// TI - A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1552 DO - 10.1158/1078-0432.CCR-14-1552 ID - Reiss2015 ER - TY - JOUR AU - Plummer, R. PY - 2008 DA - 2008// TI - Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-1223 DO - 10.1158/1078-0432.CCR-08-1223 ID - Plummer2008 ER - TY - JOUR AU - Swisher, E. M. PY - 2014 DA - 2014// TI - ARIEL 2/3: an integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response JO - J Clin Oncol VL - 32 ID - Swisher2014 ER - TY - JOUR AU - Jones, P. PY - 2015 DA - 2015// TI - Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination JO - J Med Chem VL - 58 UR - https://doi.org/10.1021/jm5018237 DO - 10.1021/jm5018237 ID - Jones2015 ER - TY - JOUR AU - Wang, L. PY - 2012 DA - 2012// TI - MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9770-x DO - 10.1007/s10637-011-9770-x ID - Wang2012 ER - TY - JOUR AU - Sandhu, S. K. PY - 2013 DA - 2013// TI - The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70240-7 DO - 10.1016/S1470-2045(13)70240-7 ID - Sandhu2013 ER - TY - STD TI - A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens. https://clinicaltrials.gov/ct2/show/NCT02354586. UR - https://clinicaltrials.gov/ct2/show/NCT02354586 ID - ref46 ER - TY - STD TI - A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01847274. UR - https://clinicaltrials.gov/ct2/show/NCT01847274 ID - ref47 ER - TY - JOUR AU - Shen, Y. PY - 2013 DA - 2013// TI - BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1391 DO - 10.1158/1078-0432.CCR-13-1391 ID - Shen2013 ER - TY - JOUR AU - Smith, M. A. PY - 2015 DA - 2015// TI - Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 JO - Pediatr Blood Cancer VL - 62 UR - https://doi.org/10.1002/pbc.25201 DO - 10.1002/pbc.25201 ID - Smith2015 ER - TY - JOUR AU - Murai, J. PY - 2014 DA - 2014// TI - Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0803 DO - 10.1158/1535-7163.MCT-13-0803 ID - Murai2014 ER - TY - STD TI - Litton JK, et al. A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Journal of Clinical Oncology. 2015;33(15):Suppl 5001. ID - ref51 ER - TY - JOUR AU - Calabrese, C. R. PY - 2004 DA - 2004// TI - Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh005 DO - 10.1093/jnci/djh005 ID - Calabrese2004 ER - TY - JOUR AU - Pernin, V. PY - 2014 DA - 2014// TI - PARP inhibitors and radiotherapy: rational and prospects for a clinical use JO - Cancer Radiother VL - 18 UR - https://doi.org/10.1016/j.canrad.2014.05.012 DO - 10.1016/j.canrad.2014.05.012 ID - Pernin2014 ER - TY - JOUR AU - Hirai, T. PY - 2012 DA - 2012// TI - Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation JO - Cancer Sci VL - 103 UR - https://doi.org/10.1111/j.1349-7006.2012.02268.x DO - 10.1111/j.1349-7006.2012.02268.x ID - Hirai2012 ER - TY - JOUR AU - Rottenberg, S. PY - 2008 DA - 2008// TI - High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0806092105 DO - 10.1073/pnas.0806092105 ID - Rottenberg2008 ER - TY - JOUR AU - Henneman, L. PY - 2015 DA - 2015// TI - Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer JO - Proc Natl Acad Sci U S A VL - 112 UR - https://doi.org/10.1073/pnas.1500223112 DO - 10.1073/pnas.1500223112 ID - Henneman2015 ER - TY - JOUR AU - Bunting, S. F. PY - 2010 DA - 2010// TI - 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks JO - Cell VL - 141 UR - https://doi.org/10.1016/j.cell.2010.03.012 DO - 10.1016/j.cell.2010.03.012 ID - Bunting2010 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2013 DA - 2013// TI - Mechanisms of resistance to therapies targeting BRCA-mutant cancers JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3369 DO - 10.1038/nm.3369 ID - Lord2013 ER - TY - JOUR AU - Nakagawa, Y. PY - 2015 DA - 2015// TI - NF-kappaB signaling mediates acquired resistance after PARP inhibition JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.2868 DO - 10.18632/oncotarget.2868 ID - Nakagawa2015 ER - TY - JOUR AU - Higuchi, T. PY - 2015 DA - 2015// TI - CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0044 DO - 10.1158/2326-6066.CIR-15-0044 ID - Higuchi2015 ER - TY - STD TI - A Phase 1–2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer. 12/05/15]; Available from: https://clinicaltrials.gov/ct2/show/NCT02571725. UR - https://clinicaltrials.gov/ct2/show/NCT02571725 ID - ref61 ER - TY - STD TI - Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02484404. UR - https://clinicaltrials.gov/ct2/show/NCT02484404 ID - ref62 ER - TY - STD TI - Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors. 9/2/2015]; Available from: https://clinicaltrials.gov/ct2/show/NCT01434316. UR - https://clinicaltrials.gov/ct2/show/NCT01434316 ID - ref63 ER -